NCT02981459View on ClinicalTrials.gov

Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

PHASE4WithdrawnINTERVENTIONAL

0

Timeline

Start Date

December 8, 2017

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions

Urinary Frequency/UrgencyBladder IrritableBladder Pain Syndrome

Interventions

DRUG

Mirabegron

daily mirabegron 25mg with the option to increase dose based on symptoms to 50mg daily after 4 weeks

Trial Locations (1)

14222

UBMD Obstetrics and Gynecology, Buffalo

Sponsors

Collaborators (1)

Astellas Pharma Inc

All Listed Sponsors

collaborator

Astellas Pharma Inc

INDUSTRY

lead

State University of New York at Buffalo

OTHER

NCT02981459 - Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women | Biotech Hunter | Biotech Hunter